Author:
Chen Wen-Jie,Yu Xia,Lu Yu-Qiang,Pfeiffer Ruth M.,Ling Wei,Xie Shang-Hang,Wu Zhi-Cong,Li Xue-Qi,Fan Yu-Ying,Wu Biao-Hua,Wei Kuang-Rong,Rao Hui-Lan,Huang Qi-Hong,Guo Xiang,Sun Ying,Ma Jun,Liu Qing,Hildesheim Allan,Hong Ming-Huang,Zeng Yi-Xin,Ji Ming-Fang,Liu Zhi-wei,Cao Su-Mei
Abstract
AbstractPurposeTo estimate the effectiveness of an Epstein–Barr virus (EBV) serology-based screening program to reduce nasopharyngeal carcinoma (NPC) mortality in a cluster randomized controlled trial in an NPC high-risk population.MethodsSixteen towns in Sihui and Zhongshan Cities, China were selected; eight were randomly allocated to the screening group and eight to the control group. Cantonese residents aged 30-69 years with no history of NPC were included January 1, 2008 to December 31, 2015. Residents in the screening towns were invited to undergo serum EBV VCA/EBNA1 IgA antibody tests; others received no intervention. Screening lasted through December 31, 2015; the population was followed through December 31, 2017.ResultsA total of 175,037 residents in the screening group and 184,526 residents in the control group were included. NPC incidence was similar in screening and control groups. A 28% reduction in NPC mortality was observed in the screening versus control arms in the overall study population (8.0 NPC deaths per 1000 person years versus 11.1; adjusted rate ratio [aRR]=0.72; 95% confidence interval=0.48-1.09; p=0.12). A stronger benefit was observed among individuals aged >50 (aRR=0.63; p=0.048) compared to those <50 (aRR 0.93; p=0.75). The reduction was increased among individuals from towns randomized to screening who participated in the screening program (aRR=0.38, p=0.001).ConclusionIn this near 10-year trial, serology EBV VCA and EBNA1 IgA antibody testing led to a reduction in NPC mortality, particularly among individuals aged ⩾50. EBV antibody-based screening for NPC is effective at reducing NPC mortality in high-risk populations.Trial registration numberNCT00941538
Publisher
Cold Spring Harbor Laboratory
Reference29 articles.
1. Ferlay J EM , Lam F , Colombet M , Mery L , Piñeros M , Znaor A , Soerjomataram I , Bray F. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [08 04 2022].
2. Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment;European journal of cancer,2017
3. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study);Oral oncology,2018
4. The Enigmatic Epidemiology of Nasopharyngeal Carcinoma
5. Epidemiology of nasopharyngeal carcinoma
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献